ArticleBMC musculoskeletal disorders2025
Platelet-rich plasma treatment for large joint osteoarthritis: retrospective study highlighting a possible treatment protocol with long-lasting stimulation of the joint with an adequate dose of platelets.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in Innovative Surgical Implant Manufacturing for Hernia Repair and Soft Tissue Reconstruction.Bioengineering (Basel, Switzerland) · 2025Review
- Osteoarthritis: multitissue pathology, molecular mechanisms, clinical management, and emerging precision and regenerative therapies.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich plasma (PRP) therapy has emerged as a potential treatment option for osteoarthritis (OA) due to its ability to promote tissue healing and anti-inflammatory effects. More evidences are needed to establish the optimal therapy protocol. We present here a retrospective analysis of 252 patients treated with PRP for big joints OA between 2020 and 2022. We aimed to evaluate the benefits of PRP combined with rehabilitation on pain and function as well as the potential prognosis factors. We observed clinically significant improvements in pain (VAS improvement 49% at 6 months, 45% at 12 months) and function (Single Assessment Numeric Evaluation i.e. SANE score improvement 44% at 6 months, 39% at 12 months). Multiple PRP shoots and high sports activity, especially competition level, were found as favorable prognosis factors. The authors would suggest offering systematically PRP therapy for competition sports practitioners. Moreover, authors suggest that multiple PRP shoots, spaced from 3 to 4 weeks, could be a viable treatment option for OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.